Blogs, insights, guides and videos on India's unlisted market — all in one place.
<h3 class="p1"><strong>Dear Valued Subscribers,</strong></h3> <p class="p2">We are back with some riveting updates on Sterlite Power, a leading player in the Indian power sector.<span class="Apple-converted-space"> </span>As your trusted advisors in the Pre-IPO market, it's our duty to keep you abreast of pivotal shifts that<span class="Apple-converted-space"> </span>could influence your investment strategy. Today, we delve into Sterlite Power's latest strategic moves,<span class="Apple-converted-space"> </span>which include a business demerger and a subsequent IPO.</p> <h3 class="p3"><strong>Demerger of Infra Business: Birth of SGL5</strong></h3> <p class="p4">In a landmark decision made in September 2023, Sterlite Power has opted to demerge its infrastructure business<span class="Apple-converted-space"> </span>into a separate entity named SGL5. This is not just a corporate restructure; it is a joint venture with Singapore's<span class="Apple-converted-space"> </span>sovereign wealth fund GIC. GIC is anticipated to invest a colossal $500 Million for a 49% stake, valuing the separated transmission business at approximately INR 8000 Cr.</p> <h3 class="p3"><strong>Sterlite Power Post-Demerger</strong></h3> <p class="p2">Post this demerger, Sterlite Power will primarily consist of its Products, MSI, and Convergence businesses,<span class="Apple-converted-space"> </span>collectively valued at around INR 9000 Cr. This move strategically positions Sterlite Power to focus on its<span class="Apple-converted-space"> </span>core competencies while leveraging the strength of GIC in the infrastructure business.</p> <p>Check our video on Product, MSI and Convergence Business Valuation -<br /><br /><iframe style="width: 370px; height: 208px;" title="YouTube video player" src="https://www.youtube.com/embed/EU0C9Wpl7yQ?si=Hy_kJmDufCx1OjBP" width="370" height="208" frameborder="0" allowfullscreen="allowfullscreen"></iframe></p> <h3 class="p3"><strong>Regulatory Approvals</strong></h3> <p class="p2">The company has already filed for the demerger with the National Company Law Tribunal (NCLT). The entire process is<span class="Apple-converted-space"> </span>expected to conclude within 8-9 months, paving the way for its much-anticipated IPO.</p> <h3 class="p3"><strong>Shareholding Structure</strong></h3> <p class="p2">For every share you hold in Sterlite Power, you will be entitled to receive one share in the newly formed SGL5,<span class="Apple-converted-space"> </span>effectively doubling your investment avenues.</p> <h3 class="p3"><strong>Financials at a Glance</strong></h3> <p class="p4">The overall order book for the Products, MSI, and Convergence business stood at INR 3400 Cr for H1FY23.<span class="Apple-converted-space"> </span>With the demerger, the total business value before the split is estimated at INR 17,000 Cr. With a total of 12 Cr outstanding shares, this pegs the per-share value at approximately INR 1400. Currently, it is available at around INR 600 per share in the unlisted market. But whoever wants to invest have to wait for 2 years minimum to get value unlocking. So, invest accordingly.</p> <h3 class="p3"><strong>What's Next: The IPO</strong></h3> <p class="p4">Once the demerger is complete, Sterlite Power is expected to go public. This IPO represents not just a liquidity event<span class="Apple-converted-space"> </span>but a milestone in the company's journey toward sustainable growth.</p> <h3 class="p3"><strong>Conclusion</strong></h3> <p class="p2">The strategic reorganization of Sterlite Power into two distinct entities serves as a groundbreaking development,<span class="Apple-converted-space"> </span>opening new investment horizons. It's not just a demerger; it's a transformation that offers diversified avenues for<span class="Apple-converted-space"> </span>both Sterlite Power and its investors.</p> <p class="p2">If you are intrigued and want to explore investment opportunities in Sterlite Power's Pre-IPO shares, feel free to reach<span class="Apple-converted-space"> </span>out to us.</p>
<div class="min-h-[20px] flex flex-col items-start gap-3 overflow-x-auto whitespace-pre-wrap break-words"> <div class="markdown prose w-full break-words dark:prose-invert light"> <h4>A) Introduction</h4> The financial sector in India has seen a flurry of Initial Public Offerings (IPOs) recently, with Capital Small Finance Bank being the latest entrant. Having filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Bank of India (SEBI), the bank is poised to raise ₹450 crore through a fresh issue and an additional 2.4 million shares via an Offer for Sale (OFS). This blog aims to provide an in-depth analysis of the upcoming IPO, focusing on key areas like the bank's financial performance and valuation metrics. <h4>B) What is Capital Small Finance Bank?</h4> Capital Small Finance Bank commenced its operations in 2016 and has since focused on secured lending. As a small finance bank, it plays a critical role in driving financial inclusion in India, offering banking services to underserved sections of the society. The Bank pioneered in bringing modern banking facilities to the rural areas at a low cost. From day one 7-Day Branch Banking was introduced with extended banking hours. The focus to serve the common man and the local touch advantages has given the Bank a competitive edge over other banks operating in the region. Within a short period, most of the Branches become market leaders of their respective centers. The Bank is providing a safe, efficient, and service-oriented repository of savings to the local community while reducing their dependence on moneylenders by making need-based credit easily available. <h4>C) IPO Details</h4> <strong>1. Fresh Issue</strong> The fresh issue of equity shares aims to raise ₹450 crore primarily to boost the bank's Tier-I capital base, thereby strengthening its financial stability. <br /><br /><strong>2. Offer for Sale (OFS)</strong> The OFS includes shares from multiple investors such as Oman India Joint Investment Fund II, PI Ventures, and Amicus Capital, among others. <h4>D) Financial Performance</h4> <strong>1. Gross Advances</strong>: ₹5,507 crore <br /><br /><strong>2. Deposits</strong>: ₹6,561 crore <br /><br /><strong>3. Revenue</strong>: ₹725 crore <br /><br /><strong>4. Profit After Tax (PAT)</strong>: ₹94 crore <br /><br /><strong>5. Book Value</strong>: ₹178 <br /><br />The bank has showcased impressive growth in its financial metrics, with a considerable rise in gross advances and net profit, indicating robust operational efficiency. <h4>E) Valuation</h4> Currently, the price of the unlisted shares stands at ₹450. <br /><br />To calculate the Price-to-Book (P/B) ratio:<br /><br /> <div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml">P/B Ratio=450/178 = 2.53x<br /></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="mord"><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist-s"></span></span></span></span></span></span></span></span></span></div> </div> </div> <div class="min-h-[20px] flex flex-col items-start gap-3 overflow-x-auto whitespace-pre-wrap break-words"> <div class="markdown prose w-full break-words dark:prose-invert light">The Price-to-Book (P/B) ratio for Capital Small Finance Bank, based on the unlisted share price, is approximately 2.53. This valuation suggests that the shares are trading at a multiple of 2.53 times their book value, making it an important metric for potential investors to consider in their analysis. <h4>Conclusion</h4> Capital Small Finance Bank's upcoming IPO appears to be a well-calculated move to solidify its capital base and facilitate future expansion. The financial performance and valuation metrics are promising, but as always, investors should perform due diligence before making investment decisions. For more detailed information, you can visit <a href="https://unlistedzone.com/shares/buy-sell-share-price-capital-small-finance-bank-sfb-unlisted-shares/" target="_new" rel="noopener">UnlistedZone</a>. <h4>Disclaimer</h4> This blog is intended solely for informational purposes and should not be construed as financial advice. Always consult a qualified financial advisor before making any investment decisions.</div> </div>
<h3>Introduction</h3> <p>ESDS Software Solution Ltd is a leading player in the Cloud and Data Centre industry. The company has been offering versatile and robust solutions to a broad range of industries including but not limited to, banking, healthcare, and government sectors. As the company is poised to go public soon, it is crucial for investors to understand the dynamics of its performance in FY 2023, as well as the prospects it holds for the future.</p> <h4>A) Financial Performance in FY 2023</h4> <p><strong>1. Revenue and Operational Costs</strong> <br /><br />While the revenue saw a moderate increase from INR 195 crores in FY 2022 to INR 205 crores in FY 2023, the operational costs have surged significantly. Employee benefit expenses alone rose by INR 7 crores, and other operational expenses increased by INR 18 crores. This increment in operational costs has resulted in a 7% dip in EBITDA margins, a significant pressure point for the company. <br /><br /><strong>2. Debt and Interest Costs</strong> <br /><br />The company's total debt has escalated to approximately INR 136 crores in FY 2023, from INR 110 crores in the previous fiscal year. Subsequently, the interest cost has also surged from INR 17 crores to INR 25 crores, raising concerns about the company's debt management. <br /><br /><strong>3. Silver Lining</strong> <br /><br />Despite the operational challenges, the company managed to generate cash from operations of approximately INR 54 crores, an increase from INR 31 crores in FY 2022. This uptick is primarily due to high Depreciation and Amortization (D&A) which is a non-cash item, suggesting underlying operational strength.</p> <h4>B) Business Updates in FY 2023</h4> <p><strong>1. New Launches and Customer Relationships</strong> <br /><br />ESDS has expanded its footprint by launching new Data Centres in Mohali and has plans for one in Navi Mumbai in H1FY24. The company has also strengthened its relationship with existing customers like L&T, EDF, and Tech Mahindra, who have scaled up their businesses significantly with ESDS. <br /><br /><strong>2. Revenue Recognition and New Orders</strong> <br /><br />Several new projects and contracts have been bagged, projecting a promising revenue stream for the upcoming fiscal years. The Mohali Data Centre alone has secured an order worth INR 25.40 crores, indicating robust revenue recognition in the near future.</p> <h4>C) Upcoming IPO and Valuation</h4> <p>ESDS issued 1,322,500 shares at INR 220 per share. With a total of approximately 9.28 crore outstanding shares, the company is currently valued at around INR 2041 crores. With its IPO on the horizon, ESDS presents an intriguing option for investors. To invest in ESDS's unlisted shares, you can contact <a href="http://www.unlistedzone.com">UnlistedZone</a>, India's leading Pre-IPO Shares Provider.</p>
<h4>Introduction</h4> <p>Pharmeasy, a significant player in India's digital pharmacy landscape, has recently announced its plan to raise INR 3500 Cr through a Right Issue of Compulsorily Convertible Preference Shares (CCPS) B. This move has stirred interest and curiosity among investors and industry experts alike. This blog aims to dissect the nuances of this financial action, its impact on the company's valuation, and what it means for potential and current investors.</p> <h4>Why is Pharmeasy Raising Capital?</h4> <p>The primary reason behind raising this massive amount is to pay back a loan that Pharmeasy took from Goldman Sachs. According to the original loan agreement, Pharmeasy was supposed to raise future capital through equity. However, Goldman Sachs extended this deadline to July 2023, providing the company with the flexibility to opt for issuing CCPS B.</p> <h4>Investor Commitment: A Confidence Booster</h4> <p>MEMG International India Private Limited, which is wholly owned by Dr. Ranjan Pai and his family, along with other co-investors, have already committed around INR 1300 Cr. Such a significant commitment not only instills confidence among other investors but also underlines the robust financial planning behind this Right Issue.</p> <h4>The Nature of CCPS B</h4> <p>These are not regular equity shares. They are Compulsorily Convertible Preference Shares (CCPS B), and they are being issued at INR 96.8 per share. Eligibility for this issue is open to holders of API Holdings’ equity shares, CCPS A, or ESOPS as of August 11, 2023.</p> <h4>The Conversion Game: Decoding the Price</h4> <p>The market was abuzz with rumors suggesting a Right Issue price of INR 4.84 per share. However, the actual price stands at INR 96.8. Now, the catch here is that these CCPS B can be converted into 20 equity shares at a future date. So, in essence, the effective price becomes INR 4.84, aligning with the market whispers.</p> <h4>Subscription Ratio</h4> <p>For every 17 equity shares you hold, you will be entitled to receive 1 CCPS B. These shares offer considerable flexibility, as they can be converted into equity shares whenever the investor chooses to do so.</p> <h4>Past Context: CCPS A Conversion</h4> <p>For investors who participated in last year’s Right Issue involving CCPS A, the conversion price has been fixed at INR 4.356 per CCPS A, following a Board meeting held on July 24, 2023.</p> <h4>Valuation Post Right Issue</h4> <p>Now, let's dive deep into the valuation metrics. Currently, the company holds:</p> <p>a) Equity Shares: 614 Cr</p> <p>b) CCPS A: 5.48 Cr</p> <p>c) CCPS B: 36.1 Cr ( After Successful Right Issue )</p> <p>If we assume that all these shares are converted into equity, we'll have a total of 1456 Cr shares (614 Cr from existing equity shares, 120 Cr from CCPS A, and 722 Cr from CCPS B). With an assumed share price of INR 5, the valuation will be approximately INR 7280 Cr or close to 1 Billion USD.</p> <h4>Timelines and Objectives</h4> <p>The Right Issue is scheduled to be open from September 29, 2023, to October 27, 2023. The funds raised through this Right Issue will be utilized for debt repayment, fulfilling working capital needs, and maintaining specific cash reserves, as mandated by the agreements with debtors.</p> <h4>Conclusion: A Strategic Lifeline and Bright Prospects Ahead</h4> <p>The Right Issue of CCPS B provides Pharmeasy with a significant capital infusion, offering the company a new lifeline for growth and innovation. Additionally, this capital raise will extinguish the debt obligations to Goldman Sachs, further strengthening the company’s balance sheet. If you examine the financials for FY23, you'll notice a drastic reduction in losses—from approximately INR 4000 Cr in FY22 to around INR 2200 Cr in FY23. This improvement in the bottom line indicates effective cost management and possibly increasing revenue streams. Based on this trend, we believe that the company is well-positioned to perform strongly in the next two years.</p> <h4>Investment Dilemma: Unlisted Market Shares or Right Issue?</h4> <p>For those contemplating an investment in Pharmeasy, the quandary often boils down to whether to buy shares from the unlisted market or to apply in the Right Issue. Our analysis suggests that applying in the Right Issue would be more advantageous as it offers shares at a more attractive price point. This Right Issue, therefore, not only solidifies Pharmeasy's financial standing but also presents an enticing investment opportunity for those looking to capitalize on the company's future growth.</p>
<h4>Introduction</h4> <p>In a recent interview with CNBC-TV 18, Sunil Raina, President and Business Head of Lava, shed light on the company's ambitious plans for the future. From focusing on contract manufacturing to embracing 5G technology, Lava aims to be a game-changer in the industry. This blog delves into the key takeaways from the interview and what they mean for the future of Lava and the Indian smartphone market.</p> <h4>Contract Manufacturing and Localization: The New Mantras</h4> <p>Lava's Biz President, Sunil Raina, emphasized the company's push towards contract manufacturing. The brand has also welcomed the Indian government's import curbs on laptops, tablets, and personal computers. With 100% manufacturing and 40% localization already achieved in India, Lava is setting new benchmarks for the industry.</p> <h4>Emotional Appeal Backed by Quality</h4> <p>While the emotional appeal of 'Made in India' resonates with the masses, Lava understands that it needs to be backed by quality products. Significant investments have been made in product development to ensure that the brand stands up to global standards.</p> <h4>The 5G Revolution: Democratizing Technology</h4> <p>The affordable 5G segment is witnessing increasing competition, and Lava aims to be a significant player in this space. With plans to launch 100 models within a year, the company is committed to making 5G accessible to the masses. Lava was among the first to introduce an affordable 5G smartphone, proving its mettle against global competitors.</p> <h4>Policy and Ecosystem: The Road Ahead</h4> <p>While Lava has achieved significant localization, the brand acknowledges that localizing bigger components like chipsets and memory is still a couple of years away. A policy tweak may be required to foster the local ecosystem further.</p> <h4>India's Focus on Innovation and R&D</h4> <p>The Indian government's import restrictions have sparked a discussion within the domestic manufacturing industry. While the industry push is to delay the implementation, Lava believes that change, although uncomfortable, is necessary for growth in manufacturing.</p> <h4>Global Expansion: South America and Beyond</h4> <p>Lava is not just limiting its vision to India. The company is actively looking at acquisitions in South America and exploring contract manufacturing as a potential growth trajectory. It aims to become the Foxconn of India, providing world-class manufacturing services.</p> <h4>Organic and Inorganic Means of Growth</h4> <p>Lava has already acquired a company with a presence in 21 countries in Latin America. This acquisition is part of the brand's strategy to grow both organically and inorganically.</p> <h4>Conclusion: Building a Global Indian Brand</h4> <p>Lava's aspiration is clear: to build a strong Indian brand that can go global. The company is not open to the idea of being acquired by a larger player, emphasizing its commitment to becoming a multinational global smartphone brand. As you've seen, Lava is not just another smartphone company; it's a brand with a vision, aiming for global expansion and technological innovation. With its focus on contract manufacturing, 5G technology, and localization, Lava presents a unique investment opportunity that's poised for significant growth. <br /><br /><strong>Why wait for the IPO when you can invest today and be part of this incredible journey?</strong> 👉 <br /><br /><strong>Contact Us Now to Learn More About Investing in <a href="https://unlistedzone.com/shares/lava-international-limited-share-price-buy-sell-unlisted-shares-of-lava-international/">Lava's Unlisted Shares.</a></strong></p>
<h2>Introduction</h2> <p>The financial landscape of the pharmaceutical industry is ever-changing, and Martin and Harris have been a significant player in this sector. The company has recently released its financial results for the fiscal year 2023, and there are some interesting takeaways. While the company has shown a decent growth in revenue, the Profit After Tax (PAT) and Earnings Per Share (EPS) have remained flat. In this article, we will delve deep into the financials of Martin and Harris, focusing on key metrics like revenue, PAT, and EPS. We will also discuss the impact of increased expenses on the company's bottom line.</p> <h2>Revenue Growth: A Positive Sign</h2> <table dir="ltr" border="1" cellspacing="0" cellpadding="0"><colgroup> <col width="189" /> <col width="100" /> <col width="100" /></colgroup></table> <table style="width: 60.7046%;" width="100%"> <tbody> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Particulars (in Cr)"}">Particulars (in Cr)</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":2023}">2023</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":2022}">2022</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Revenue From Operations"}">Revenue From Operations</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":205}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">205</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":186}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">186</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Cost of Material Consumed"}">Cost of Material Consumed</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":47}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">47</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":50}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">50</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Employees Benefit Expenses"}">Employees Benefit Expenses</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":25}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">25</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":19}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">19</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Other Expenses"}">Other Expenses</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":61}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">61</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":46}">46</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"EBITDA"}">EBITDA</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":72}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-4]C[0]-R[-3]C[0]-R[-2]C[0]-R[-1]C[0]">72</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":71}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-4]C[0]-R[-3]C[0]-R[-2]C[0]-R[-1]C[0]">71</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"OPM"}">OPM</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":0.35121951219512193}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}" data-sheets-formula="=R[-1]C[0]/R[-5]C[0]">35.12%</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":0.3817204301075269}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}" data-sheets-formula="=R[-1]C[0]/R[-5]C[0]">38.17%</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Other Income"}">Other Income</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":24}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">24</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":26}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">26</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Depreciation"}">Depreciation</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":4}">4</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":4}">4</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Finance Cost"}">Finance Cost</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":0}">0</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":0}">0</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"PBT"}">PBT</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":92}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-5]C[0]+R[-3]C[0]-R[-2]C[0]">92</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":93}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-5]C[0]+R[-3]C[0]-R[-2]C[0]">93</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Tax"}">Tax</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":24}">24</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":23}">23</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"PAT"}">PAT</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":68}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">68</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":70}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">70</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"NPM"}">NPM</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":0.29694323144104806}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}" data-sheets-formula="=R[-1]C[0]/(R[-12]C[0]+R[-6]C[0])">29.69%</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":0.330188679245283}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}" data-sheets-formula="=R[-1]C[0]/(R[-12]C[0]+R[-6]C[0])">33.02%</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"Shares"}">Shares</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":0.399}">0.399</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":0.399}">0.399</td> </tr> <tr> <td style="width: 40.7159%;" data-sheets-value="{"1":2,"2":"EPS"}">EPS</td> <td style="width: 28.5999%;" data-sheets-value="{"1":3,"3":170.42606516290726}" data-sheets-numberformat="{"1":2,"2":"0.00","3":1}" data-sheets-formula="=R[-3]C[0]/R[-1]C[0]">170.43</td> <td style="width: 30.6842%;" data-sheets-value="{"1":3,"3":175.43859649122805}" data-sheets-numberformat="{"1":2,"2":"0.00","3":1}" data-sheets-formula="=R[-3]C[0]/R[-1]C[0]">175.44</td> </tr> </tbody> </table> <p>On a standalone basis, Martin and Harris have reported a revenue of 207 Cr for FY23, which is a commendable 20% increase from the 172 Cr in FY22. This growth indicates a strong performance in the company's core pharma business and suggests that the company has been able to capitalize on market opportunities effectively.</p> <h2>Flat Profit: A Closer Look</h2> <p>Despite the impressive revenue growth, the company's PAT remained flat at 53 Cr. The reason behind this stagnation can be traced back to the Profit and Loss (P&L) statement. The employee benefit expenses have increased from 18 Cr in FY22 to 24 Cr in FY23. Additionally, other expenses have surged from 44 Cr to 60 Cr in the same period. This amounts to an overall increase in expenses by almost 22 Cr.</p> <h3>Breakdown of Expenses</h3> <p>A significant portion of the increased expenses comes from legal and professional fees, along with consultancy charges, which have seen a 7 Cr increase. These rising costs have offset the revenue growth, leading to a flat PAT and EPS.</p> <h2>Subsidiary Performance: Delite Infrastructure</h2> <p>Delite Infrastructure, a subsidiary of Martin and Harris, primarily earns its income from Rent and Interest. The income for FY23 remained around 21 Cr, similar to the 25 Cr in the previous year.</p> <h2>Consolidated Financials</h2> <p>On a consolidated level, the revenue for FY23 was 229 Cr compared to 212 Cr in FY22. The PAT was 68 Cr in FY23, slightly lower than the 70 Cr in FY22. The EPS for FY23 stood at approximately 170.</p> <h2>Conclusion: A Mixed Bag</h2> <p>To sum up, Martin and Harris have shown promising growth in their pharma business with a 20% increase in revenue. However, the increased expenses have negated the impact of this growth on the PAT. Investors looking at Martin and Harris Unlisted Share Price should consider these factors carefully. For those interested in investing in <a href="https://unlistedzone.com/shares/martin-and-harris-laboratories-limited-unlisted-shares/">Martin and Harris Unlisted Share</a>, it's crucial to weigh the growth prospects against the rising operational costs. While the top line shows promise, the bottom line needs careful evaluation</p>
<h4>Introduction</h4> <p>In the increasingly complex landscape of India's financial sector, Tata Capital stands as a beacon of trust and versatility. As a significant arm of the globally recognized Tata Sons Limited, the firm offers a diverse and comprehensive suite of financial services. This article aims to provide an in-depth analysis, focusing on <a href="https://unlistedzone.com/shares/tata-capital-limited-unlisted-share/">Tata Capital Unlisted Share</a>. Specifically, it will dissect Tata Capital Unlisted Share Financials, scrutinize Tata Capital Unlisted Share Valuation, and discuss <a href="https://unlistedzone.com/5-major-risks-in-investing-in-unlisted-shares/">Tata Capital Unlisted Share Risk.</a></p> <h4>Tata Capital's Services</h4> <h4>A Wide Spectrum of Financial Solutions</h4> <ol> <li><strong>Consumer Loans</strong>: Tata Capital provides a multitude of loans catering to various individual needs, including personal loans, home loans, and auto loans. These offerings make Tata Capital Unlisted Share an attractive investment option.</li> <li><strong>Business Loans</strong>: Specializing in loans for Small and Medium Enterprises (SMEs), the performance and demand for these business loans have a substantial impact on Tata Capital Unlisted Share Financials.</li> <li><strong>Insurance Services</strong>: The firm offers a wide range of insurance products, adding another layer of versatility to Tata Capital Unlisted Share offerings.</li> <li><strong>Investment Services</strong>: Through its subsidiary, Tata Securities Limited, the company provides a plethora of investment banking services and mutual fund distribution.</li> </ol> <h4>Global Footprint: An International Perspective</h4> <p>Tata Capital's sphere of influence isn't confined to India. With strategically located international offices in financial hubs like Singapore and London, the company's global reach positively impacts Tata Capital Unlisted Share Valuation.</p> <h4>Financial Milestones: A Close Look at Tata Capital Unlisted Share Financials</h4> <h4>A Comprehensive Five-Year Growth Analysis</h4> <p>The Assets Under Management (AUM) of Tata Capital have seen a robust growth trajectory, soaring from ₹51,847 Crores in 2016-17 to ₹1,16,756 Crores in 2022-23. This growth is also mirrored in the revenue, which has escalated from ₹6,324 Crores to ₹13,637 Crores. The Profit After Tax (PAT) has significantly risen from ₹459 Crores to ₹2,946 Crores over the same period. Additionally, the Net Worth of the company has surged from ₹4,210 Crores to ₹16,959 Crores.</p> <h4>How It Reflects on Tata Capital Unlisted Share Financials</h4> <p>This impressive increase in AUM, revenue, PAT, and Net Worth not only reflects a strong financial standing but also has positive implications on Tata Capital Unlisted Share Financials. However, the valuations of Tata Capital is already overvalued in the unlisted market.</p> <h4>Tata Capital Unlisted Share Valuation: A Critical Assessment</h4> <h4>Current Market Valuation: An Overview</h4> <p>As of the latest data, Tata Capital Unlisted Shares are trading between ₹500 to ₹520 per share. With a book value as of 31st March 2023 standing at approximately ₹50 per share, this equates to a Price-to-Book (P/B) ratio of over 10x.</p> <h4>Tata Capital Unlisted Share Risk: A Caution on Valuation</h4> <p>This elevated P/B ratio, which is significantly above the industry average, raises Tata Capital Unlisted Share Risk factors associated with overvaluation. Investors need to exercise due diligence and approach this investment opportunity with caution.</p> <h4>Comparison with Upcoming Rights Issue</h4> <p>The company has announced a rights issue at ₹162 per share, which creates an even greater urgency to examine Tata Capital Unlisted Share Valuation critically. This substantial difference between the rights issue price and the current trading price further amplifies the risks of overvaluation.</p> <h4>Investor Advisory: Exercise Caution</h4> <p>Due to the high Tata Capital Unlisted Share Valuation and the discrepancy in the rights issue price, investors are advised to exercise extreme caution. A detailed risk assessment is crucial for understanding Tata Capital Unlisted Share Risk before making any investment decisions.</p> <h4>Conclusion: A Balanced Perspective</h4> <p>Tata Capital has exhibited impressive growth metrics and offers a broad and diversified portfolio of services. However, the current Tata Capital Unlisted Share Valuation demands that investors approach this investment opportunity with a balanced perspective and an informed mind. Due diligence is especially critical considering the upcoming rights issue and the apparent high valuation of Tata Capital Unlisted Shares.</p>
<p>Merino Industries Limited (MIL) has released its annual financial report for the fiscal year 2022-23, providing valuable insights into its financial performance across key indicators. <br /><br /><strong>Financial Performance Highlights</strong> <br /><br /><strong>1. Strong Revenue Growth</strong> <br /><br />MIL achieved substantial revenue growth in FY 2022-23, with a notable increase of 23.06%. Revenues surged to Rs. 2,205 crore, up from Rs. 1,792 crore in FY 2021-22. <br /><br /><strong>2. Increase in Total Expenses</strong> <br /><br />The company's total expenses also saw a significant uptick, rising by 25% to reach Rs. 2,031 crore compared to Rs. 1,618 crore in FY 2021-22. <br /><br /><strong>3. EBITDA Growth</strong> <br /><br />MIL's EBITDA increased by 7.35% in FY 2022-23, reaching Rs. 270 crore, compared to Rs. 251 crore in FY 2021-22. <br /><br /><strong>4. Exports on the Rise</strong> <br /><br />Exports exhibited a growth of 20.07%, with figures climbing to Rs. 640 crore in FY 2022-23 from Rs. 533 crore in FY 2021-22. <br /><br /><strong>5. Net Profit Decline</strong> <br /><br />In FY 2022-23, the company's net profit decreased by 10%, settling at Rs. 117 crore, compared to Rs. 131 crore. This decline was primarily driven by increased raw material prices, repayment of unsecured loans, and higher finance costs. <br /><br /><strong>Balance Sheet Overview</strong> <br /><br /><strong>1. Net Asset Growth</strong> MIL reported a 25% increase in net assets, which reached Rs. 2,310 crore in FY 2022-23, up from Rs. 1,845 crore in FY 2021-22. <br /><br /><strong>2. Equity and Liabilities</strong> The net equity and liabilities of the company also showed a 25% increase, amounting to Rs. 2,310 crore in FY 2022-23, compared to Rs. 1,845 crore in FY 2021-22.<br /><br /><strong>Insights from Cash Flow Statement</strong> <br /><br /><strong>1. Operating Activities Cash Flow</strong> <br /><br />MIL generated Rs. 184 crore in net cash from operating activities in FY 2022-23, compared to Rs. 128 crore in FY 2021-22. <br /><br /><strong>2. Investing Activities Cash Flow</strong> <br /><br />The company's net cash used in investing activities amounted to Rs. (458) crore in FY 2022-23, a significant change from Rs. (219) crore in FY 2021-22. <br /><br /><strong>3. Financial Activities Cash Flow</strong> <br /><br />MIL experienced a boost in net cash generated from financial activities, amounting to Rs. 246 crore in FY 2022-23, compared to Rs. 103 crore in FY 2021-22. Merino is a leading integrated manufacturer and marketer of interior solutions. With the commitment to innovation and investment in enhancing and diversifying its product portfolio, the Company offers a diverse bouquet of multiple surfaces with infinite design possibilities that showcase the world-class manufacturing prowess. Headquartered in Kolkata, the Company has a strong presence in all major states in India and exports its products to 81 countries worldwide. The Company is managed by a dynamic leadership team and a group of professionals with diverse competencies and backgrounds. <br /><br /><strong>Diverse Solutions</strong> <br /><br />The portfolio of surface solutions is designed for homes, offices, commercial and public areas. The Company has consistently focused on making the products more affordable, improving their value, and maintaining transparency. As a pioneer in the industry, the Company has continuously evolved through technological innovations, retaining its competitive advantage. Since the establishment of the first manufacturing unit for high-pressure decorative laminates in Hapur in 1981, the Company made significant progress and has enjoyed a high brand recall through decades of market presence and satisfied customers. <br /><br /><strong>Achieving Milestones in Progress</strong> <br /><br />During the year, the Company achieved remarkable progress, primarily attributed to its burgeoning market presence and increasing recognition of the brand. A consistent and noteworthy aspect of the performance has been the sustained momentum in introducing innovative products across various categories. https://unlistedzone.com/shares/merino-industries-limited-unlisted-shares/</p>
<h3>A) Business Overview</h3> <p>The company in focus is Lakeshore Hospital and Research Centre Limited (LHRC), which is a part of VPS Healthcare. LHRC is a healthcare service provider that operates mainly through one hospital and has slightly diversified by starting a Medical Centre in Kozhikode. It offers a range of services including surgeries, transplants, dialysis, and preventive health check-ups among others. As of March 31, 2022, Lakeshore Hospital and Research Centre Limited (LHRC) employs a distinguished cadre of healthcare professionals. The staff includes 254 doctors, approximately 729 nurses, more than 450 individuals in medical support roles, and nearly 429 additional support staff. Among the doctors are several high-profile experts who have been affiliated with the hospital for over 15 years. The institution also boasts 129 specialist doctors serving as full-time consultants.</p> <h3>B) Key Strengths</h3> <p><strong>1. Part of a Reputed Group</strong>: Being a part of VPS Healthcare gives LHRC a strong backing and credibility in the healthcare industry.<br /><br /></p> <p><strong>2. Strong Medical Team</strong>: LHRC has an extensive and experienced team of doctors, nursing staff, and medical support staff.<br /><br /></p> <p><strong>3. Solid Financial Performance</strong>: The Total Operating Income for FY23 witnessed a year-on-year growth of 17%, rising to ₹419 crores from ₹358 crores in FY22. Similarly, Profit After Tax (PAT) also escalated, moving from ₹42 crores in FY22 to ₹57 crores in FY23.<br /><br /></p> <p><strong>4. Diverse Specializations</strong>: The revenue streams are well-diversified across various medical specialties, mitigating risks associated with dependency on a single domain.</p> <p><strong>5. Healthy Capital Structure</strong>: The company has favorable debt protection metrics, and a low overall gearing ratio, suggesting a comfortable capital structure.</p> <h3>C) Key Weaknesses</h3> <p><strong>1. Moderate Occupancy Rates</strong>: Despite an uptick in FY23, the occupancy rates have remained moderate due to competition from lower-cost service providers.</p> <p><strong>2. Dependence on Skilled Professionals</strong>: The company’s success is heavily contingent on retaining its scarce, highly-qualified medical professionals. Plus retaining nurses is also a challenge as they get good opportunity outside India.</p> <p><strong>3. Geographical Concentration</strong>: A large portion of the company's revenue is generated from a single location, making it susceptible to local market conditions.</p> <p><strong>4. Liquidity</strong>: Though marked as strong, the company has to manage its obligations carefully, given its strong accruals.</p> <h3>D) Management Quality</h3> <p>The management of LHRC appears to be highly experienced and competent, backed by a strong promoter group in VPS Healthcare. They have successfully managed to improve both financial and operational performance over the years.</p> <h3>E) Company Inception and Growth</h3> <p>LHRC has grown over the years to become a significant part of VPS Healthcare. While details about its inception are not available in the information provided, its alignment with VPS Healthcare suggests a well-structured and strategically planned growth trajectory.</p> <h3>F) Lakeshore Hospital and Research Center Performance Overview for FY22-23</h3> <h4>Financial Metrics</h4> <p><strong>1. Total Income</strong>: The company recorded a total income of ₹424 crores for this fiscal year, which is a 17% YoY increase compared to ₹362 crores in FY22.</p> <p><strong>2. Net Profit</strong>: The net profit surged impressively by 34%, growing from ₹43 crores in FY22 to ₹58 crores in FY23.</p> <p><strong>3. Earnings Per Share</strong>: An increase in EPS from ₹4.29 to ₹5.75 demonstrates a favorable return on investment.</p> <p><strong>4. Dividend</strong>: The Board has sanctioned a dividend of ₹1.70 per share (17%), to be disbursed following the Annual General Meeting's approval.</p> <h4>Operational Metrics</h4> <p><strong>1. Patient Volumes</strong>: LHRC provided healthcare to 343,876 out-patients and 21,087 in-patients this year, a notable uptick in service delivery.</p> <p><strong>2. Foreign Patient Influx</strong>: The hospital has successfully expanded its global reach, with foreign patient numbers soaring from 6,008 to 20,047.</p> <p><strong>3. Revenue Diversification</strong>: The healthcare specializations contributing to revenue are diversified, including Nephrology, Medical Oncology, and Orthopedics, among others.</p> <p><strong>4. Organ Transplants</strong>: A significant milestone was achieved in conducting 53 liver and 212 renal transplants, with a staggering success rate above 95%.</p> <h4>Future Outlook</h4> <p>For FY23-24, the company projects a high single to mid-double-digit growth in revenue and a corresponding increase in profitability. Management has projected a turn over 473 crores and profit before tax of 117 crores for the financial year 2023-24.</p> <h4>Additional Insights</h4> <p>The Kozhikode Medical Centre, although in its nascent stage, has already catered to over 12,000 patients.</p> <h4>Risk and Compliance</h4> <p>The company adheres to government regulations, especially in sensitive areas like organ transplants.</p> <h3>G) UnlistedZone's Take</h3> <p>Based on the aforementioned data, the performance of Lakeshore Hospital and Research Center appears strong on both financial and operational fronts. The future outlook also remains bullish. This suggests a positive investment scenario for the upcoming fiscal year. <br /><br />At present, the unlisted shares of Lakeshore Hospital are trading at ₹80 per share. With a total of 10 crore outstanding shares, this results in a Market Capitalization (Mcap) of ₹800 crores. The Price-to-Earnings (P/E) ratio, based on this pricing, stands at 13x, which appears to be reasonably valued.</p>
<h2>Introduction</h2> <p>Investing in unlisted shares presents a lucrative but challenging landscape. One of the <a href="https://unlistedzone.com/5-major-risks-in-investing-in-unlisted-shares/"><strong>Key Risks in Unlisted Shares</strong></a> that often evades the spotlight is liquidity risk. This blog aims to demystify this critical aspect, using <strong>NSE Unlisted Share</strong> and <strong>Bharat Hotel Unlisted Share</strong> as examples to bring a practical perspective.</p> <h2>A) What is Liquidity Risk?</h2> <p><strong>Liquidity Risk in Unlisted Shares</strong> is the challenge an investor faces when attempting to buy or sell shares due to the absence of a centralized marketplace. In unlisted markets, trading volumes are generally low, leading to a wide bid-ask spread, which can adversely affect both buying and selling prices.</p> <h2>B) Why Liquidity Risk is a Major Concern?</h2> <h3>Limited Market Participants</h3> <p>Unlike listed shares that enjoy a vast and active market, unlisted shares are often confined to a smaller pool of institutional and high-net-worth investors. This limitation makes the shares less liquid.</p> <h3>Inventory Risk for Dealers</h3> <p>Dealers in unlisted shares often hold these shares on their balance sheets. This practice increases their own risk exposure and forces them to operate on a safety margin, which can widen the bid-ask spread.</p> <h3>Price Volatility</h3> <p>A direct consequence of low liquidity is high price volatility. Shares with limited buyers and sellers can experience extreme price swings, making them riskier investment options.</p> <h2>C) Understanding the Market Dynamics Through Real-world Examples</h2> <h3>Case Study 1: The Rise and Fall of Bharat Hotel Unlisted Shares</h3> <p>In 2018-19, the <a href="https://unlistedzone.com/shares/bharat-hotels-limited-share-price-buy-sell-unlisted-shares-of-bharat-hotels/"><strong>Bharat Hotel Unlisted Share</strong></a> was a darling among investors. Its upcoming IPO and stellar sector performance had driven the share price to ₹400. However, the IPO never materialized, and the COVID-19 pandemic in 2020 wrecked havoc on the hospitality industry, causing the share price to plummet to ₹150. The stock remained dormant for almost three years until the sector showed signs of recovery in 2023, and the share price climbed back to ₹250.</p> <h4>Lessons Learned</h4> <p>The Bharat Hotel case teaches us the importance of not solely relying on IPO plans or sector trends. Investors must carry out due diligence and be prepared for unexpected market turns that can lead to liquidity drying up.</p> <h3>Case Study 2: The Sustained Success of NSE Unlisted Shares</h3> <p>On the opposite end of the spectrum, we have <a href="https://unlistedzone.com/shares/nse-india-limited-unlisted-shares/"><strong>NSE Unlisted Shares</strong></a>, which have consistently defied liquidity risk. Priced at ₹1000 in 2019-20, the share has seen a remarkable growth, standing at ₹3300 today. Strong financials, including robust growth in revenue, EBITDA, and PAT, have kept this share in high demand. Additionally, the prospects of an upcoming IPO have only made it more appealing.</p> <h4>Lessons Learned</h4> <p>The NSE case highlights the importance of strong fundamentals and business models. Even in the absence of a formal market, shares with strong underlying businesses maintain liquidity.</p> <h2>D) Strategies to Mitigate Liquidity Risk</h2> <h3>In-Depth Research</h3> <p>Understanding the company's fundamentals, including its balance sheet, cash flows, and growth prospects, can offer insights into its liquidity.</p> <h3>Portfolio Diversification</h3> <p>Diversifying your portfolio across sectors and risk levels can help mitigate the impact of liquidity risk on your overall investment.</p> <h3>Consult Experts</h3> <p>The complexity of the unlisted market often requires specialized knowledge. Consulting experts can provide valuable insights and recommendations with players like <a href="http://www.unlistedzone.com">UnlistedZone</a> for buying unlisted shares.</p> <h2>Conclusion</h2> <p>Liquidity risk is a significant concern in the unlisted share market but is not insurmountable. A well-researched and diversified portfolio can go a long way in mitigating this risk. The contrasting tales of NSE and Bharat Hotel unlisted shares serve as vital lessons for investors looking to navigate the often tumultuous waters of unlisted markets.</p>
<p>Oravel Stays Limited, the parent Company of Oyo Rooms has recently published its annual financial report for the fiscal year 2022-23. This report uncovers significant financial trends across various parameters, including revenue, expenses, profits, and cash flows. <br /><br /><strong>Financial Performance Highlights</strong> <br /><br /><strong>1. Impressive Revenue Growth</strong> <br /><br />In FY 2022-23, Oravel Stays Limited reported an outstanding 14% increase in revenue from operations, reaching Rs. 5463 crore, up from Rs. 4781 crore in FY22. Concurrently, the company managed to reduce expenses by 2.6%, with expenses totaling Rs. 6800 crore compared to Rs. 6985 crore in FY22. The growth was primarily driven by demand recovery, resulting in revenue growth, enhanced gross margins, and streamlined fixed cost structures, ultimately contributing to long-term sustainable growth and profitability. <br /><br /><strong>2. Strong EBITDA Improvement</strong> <br /><br />The Company's consolidated adjusted EBITDA witnessed a significant improvement, reaching INR 277 crore for FY 2022-23, compared to INR (471) crore in FY 2021-22. <br /><br /><strong>3. Decrease in Loss Before Tax</strong> <br /><br />The loss before tax for the Company decreased by an impressive 39% to Rs. (1286) crore in FY23, compared to Rs. (2141) crore in FY22. Similarly, the loss for the year saw a significant reduction of 34%, amounting to Rs. (1286) crore as opposed to Rs. (1941) crore in FY22. <br /><br /><strong>Balance Sheet Overview</strong> <br /><br /><strong>1. Total Assets and Equity & Liabilities</strong> <br /><br />During FY23, the Company experienced a 6% decrease in total assets, which amounted to Rs. 7932 crore, down from Rs. 8452 crore in FY22. Correspondingly, the total equity and liabilities also decreased by 6%, totaling Rs. 7932 crore in FY23 compared to Rs. 8452 crore in FY22. <br /><br /><strong>Cash Flow Insights</strong> <br /><br /><strong>1. Strong Operating Cash Flow</strong> <br /><br />The Company generated robust net cash from operating activities in FY23, amounting to Rs. 141 crore, in stark contrast to the cash used in operating activities, which was Rs. (921) crore in FY22. <br /><br /><strong>2. Investing and Financial Activities</strong> <br /><br />Notably, there was a positive trend in cash flow from investing activities in FY23, with a net cash generation of Rs. (108) crore. This was a significant improvement from the cash used in investing activities, which was Rs. (711) crore in FY22. In addition, cash flow from financial activities showed improvement, with cash used decreasing to Rs. (704) crore in FY23, compared to the cash generated of Rs. 703 crore in FY22. <br /><br /><strong>Company Overview</strong> <br /><br />OYO is an innovative technology platform dedicated to empowering small entrepreneurs and property owners to efficiently manage and operate their hotels and homes. By offering a full-stack of technology products and services, OYO simplifies operations and provides easy-to-book, affordable accommodation options for customers. <br /><br /><strong>Business Model</strong> <br /><br />Since its inception in 2012, OYO has been at the forefront of reshaping the short-stay accommodation industry. The company has developed a unique two-sided technology platform designed to comprehensively address the pain points of both Patrons (property owners, lessors, and operators) and Customers (travelers and guests). OYO's approach helps Patrons transform their unbranded and underutilized properties into digitally enabled, branded storefronts with increased revenue potential. Simultaneously, it provides Customers access to a wide range of high-quality accommodations at compelling price points through OYO's various platforms, including the OYO app, web, mobile web, online travel agents, and corporate partnerships. <br /><br /><strong>Strategic Focus</strong> <br /><br />Throughout the year, OYO maintained its global strategy, shifting from rapid growth to sustainable growth with a heightened emphasis on profitability. The company achieved this by optimizing its cost structure, reducing General & Administrative expenses, and refining marketing investments. Simultaneously, OYO doubled down on technology and product development to ensure operational efficiency. <br /><br /><strong>IPO Plans</strong> <br /><br />Subject to obtaining the necessary approvals and fulfilling other considerations, OYO is planning an Initial Public Offering (IPO) in accordance with the applicable regulations of the Securities and Exchange Board of India (SEBI). The company has submitted a Pre-filed draft red herring prospectus dated March 30, 2023 (Pre-filed DRHP) to SEBI in connection with this IPO. <br /><br /><a href="https://unlistedzone.com/shares/oyo-share-price-buy-sell-oyo-shares/">https://unlistedzone.com/shares/oyo-share-price-buy-sell-oyo-shares/</a></p> <p> </p>
<h2>A) Introduction of SBI General Insurance Unlisted Share</h2> <p>SBI General Insurance has been a stalwart in the insurance sector in India, providing a diverse range of general insurance products since its inception in 2009. With its strong foundation and a commitment to trust and security, the company has been making strides year after year. In this blog post, we will delve into the key highlights from SBI General Insurance's 2023 Annual Report and examine the company’s performance, offerings, and future outlook. SBI General is one of the fastest growing private general insurance companies, with the strong parentage of SBI. Ever since its establishment in 2009, the growth has been exponential in various aspects. They have expanded their presence from 17 branches in 2011 to over 141 branches pan-India. SBI General Insurance demonstrates an astute strategic approach to distribution, leveraging a multi-faceted model that encompasses Bancassurance, Agency Channels, Broking Networks, Retail Direct Outlets, and Digital Collaborations. This wide-ranging network is underpinned by the formidable backbone of over 22,437 SBI branches, augmented by an extensive roster of agents, strategic financial partnerships, and Original Equipment Manufacturers (OEMs). Moreover, the company has intelligently formed multiple digital alliances to broaden its reach.</p> <h2>B) Exponential Growth and Awards</h2> <p>The company has seen exponential growth since its inception, expanding its branch network from 17 in 2011 to over 141 pan-India. In the fiscal year 2022-23 alone, the Gross Written Premium (GWP) stood at INR 10,888 crore, a growth of 17.6%. These figures indicate a robust financial position and promising prospects. SBI General Insurance has been recognized for its performance, winning the 'Insurer of the Year' award in the non-life category at the FICCI Insurance Industry Awards for 2020 and 2021. In 2022, it was named 'Best General Insurance Company of the Year' at the Third Emerging Asia Insurance Awards, a testament to its commitment and excellence.</p> <h2>C) Operational Highlights of SBI General Health Insurance</h2> <h3>i) Claims Management</h3> <p>One of the key operational highlights is the handling and settlement of claims. The company received 6,20,651 fresh claim intimations in FY23, down 24% compared to the previous year, largely due to reduced Covid-related claims in Health and negligible CAT-event-related claims in Property Lines. With a commendable claims settlement ratio of 98%, customer satisfaction remains at the forefront.</p> <h3>ii) Motor and Health Insurance</h3> <p>In the Motor OD segment, new claims went up by 12% over the previous year, mainly driven by the two-wheeler (2W) segment. In Health Insurance, the company has achieved a 95% claims settlement ratio, further solidifying its reputation as a reliable insurer.</p> <h3>iii) Commercial Lines</h3> <p>In the Commercial Lines area, the Net Promoter Score stands at 92 as of March 2023. Specialised claims management teams have been formed to handle different types of claims, including liability, trade credit, event, cyber, and crop insurance. </p> <h2>D) Digital Initiatives and Customer Focus</h2> <p>Digital transformation has been a key driver for SBI General Insurance. It has enabled the company to handle claims more efficiently and offer better services to its customers. These digital initiatives have not only reduced overheads but also increased customer satisfaction, as evidenced by the Net Promoter Scores in various segments.</p> <h2>E) Gross Written Premium SBI General Insurance Growth in Last 5 years</h2> <p>Gross Written Premium is the total premium collected by insurance companies whenever they sell insurance policy. Growth of this figure indicates how well company is growing. </p> <h2>F) Valuation and Investment Opportunity in SBI General Insurance</h2> <p>Currently, <a href="https://unlistedzone.com/shares/sbi-general-insurance-unlisted-shares/">SBI General Insurance Unlisted Share</a> is available in the unlisted market at INR 1150 per share with a Market Capitalization of INR 24,150 crore. The Mcap/GWP ratio stands at 2.2x, indicating that the company is fairly valued. For investors looking for a stable and reliable opportunity, this could be a worthy consideration.</p> <h2>G) Conclusion</h2> <p>SBI General Insurance's performance, as outlined in its 2023 Annual Report, is both promising and inspiring. The company's financial health, robust operational metrics, and customer-centric approach make it a formidable player in the Indian insurance market.</p> <hr /> <h2>FAQs for Analyzing General Insurance Companies</h2> <h3>1. What is Gross Written Premium (GWP) and how is it significant?</h3> <p><strong>Answer:</strong> GWP is the total revenue generated from premiums before any deductions like reinsurance costs. It serves as a primary revenue measure and indicates the size and market share of an insurance company.</p> <hr /> <h3>2. How does Net Written Premium (NWP) differ from GWP?</h3> <p><strong>Answer:</strong> NWP is the GWP minus premiums ceded to reinsurers. This metric provides a more accurate depiction of the revenue that the insurance company retains.</p> <hr /> <h3>3. What does Net Earned Premium (NEP) indicate?</h3> <p><strong>Answer:</strong> NEP is the portion of NWP that is earned over a specific period. It accounts for the risk covered during that period and is a better measure of the company's operational efficiency.</p> <hr /> <h3>4. Why is Claims Settlement Ratio important?</h3> <p><strong>Answer:</strong> This ratio indicates the percentage of claims settled by the insurer against the claims received. A higher ratio is generally favorable, as it signifies the company’s reliability in settling claims.</p> <hr /> <h3>5. What does the Combined Ratio reveal?</h3> <p><strong>Answer:</strong> The combined ratio is the sum of the loss ratio and expense ratio. A combined ratio under 100% indicates underwriting profitability, while a ratio over 100% suggests an underwriting loss.</p> <hr /> <h3>6. What is Mcap/GWP and how does it help in analysis?</h3> <p><strong>Answer:</strong> Mcap/GWP is the ratio of the company’s market capitalization to its Gross Written Premium. It helps in evaluating the valuation of the insurance company relative to its premium income.</p> <hr /> <h3>7. How is Claim Ratio different from Claims Settlement Ratio?</h3> <p><strong>Answer:</strong> Claim Ratio is the ratio of claims incurred to the premiums earned. It helps in assessing the profitability and risk associated with the insurance portfolio. Claims Settlement Ratio, on the other hand, focuses on the company's ability to settle claims.</p> <hr /> <h3>8. How do these metrics interact with each other?</h3> <p><strong>Answer:</strong> Understanding the interplay between these metrics can provide a holistic view of the company’s financial health. For example, a high Claims Settlement Ratio coupled with a low Combined Ratio would typically indicate a strong, customer-centric, and profitable insurer.</p> <hr /> <h3>9. Should all these metrics be used in conjunction for analysis?</h3> <p><strong>Answer:</strong> Yes, relying on a single metric may not provide a comprehensive view. Investors should consider all these metrics to make an informed decision.</p> <hr /> <h3>10. Where can I find the data for these metrics?</h3> <p><strong>Answer:</strong> These financial metrics can be found in a company's annual report, financial statements, or through regulatory filings available on stock exchange websites</p> <hr /> <p><em>Disclaimer: This blog post is for informational purposes only and should not be considered as financial advice. Always consult with your financial advisor before making any investment decisions.</em></p>
Indicative prices, company research and your enquiries — in your pocket. Get price notes on the names you follow and reach our team from anywhere.
